Trial Profile
An Open-label, Phase 2 Study of ACP-196 in Subjects With Mantle Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary)
- Indications Mantle-cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Acerta Pharma
- 19 Jan 2024 Planned End Date changed from 31 Dec 2025 to 1 Sep 2026.
- 12 Dec 2023 This trial has been completed in Netherland, according to European Clinical Trials Database record.
- 31 Jul 2023 This study has been completed in Czech Republic, according to European Clinical Trials Database.